ArticleJournal of immunotherapy and precision oncology2025

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

Karen A Autio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.